Can Molecular Imaging Find a Path to Navigate Evolving Breast Cancer Treatments?

FES PET is an FDA-approved imaging biomarker. Like IHC, FES positivity predicts clinical benefit of endocrine therapy. In addition, FES measures the target activity in endocrine agent drug development. A recent study found that whole body tumor heterogeneity of expression predicts clinical benefit, and serial FES monitors ER blockade and post treatment release.